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Abstract
In 2001, an international surveillance initiative 
was established, utilising a validated larval devel-
opment inhibition assay to track the susceptibil-
ity of cat flea isolates to imidacloprid. In 2009, an 
Australian node was incorporated into the pro-
gramme, joining laboratories in the United States 
and Europe. Field isolates of Ctenocephalides felis 
eggs were submitted to participating laboratories 
and, where egg quantity and quality was sufficient, 
were placed in the imidacloprid discriminating dose 
bioassay for evaluation. Between 2002 and 2012, a 
total of 2,307 cat flea isolates were received across 
all sites; 1,685 submissions (73 %) were suitable 
for placement into the bioassay. In the Northern 
Hemisphere, isolate submission rate was influ-
enced by season, with highest numbers submitted 
S48
EctoparasitEs 
between June and October. In Australia, pets 
with flea infestations could be sourced year-
round, and submission rate was largely influenced 
by programme factors and not climate. A total 
of 1,367 valid assays were performed between 
2002 and 2012 (assay validity data was not record-
ed in 2001); adult flea emergence 5 % or greater at 
3 ppm imidacloprid was observed in 38 of these 
assays (2.8 %). For these isolates that reached the 
threshold for further investigation, re-conduct of 
the assay using either a repeat challenge dose of 
3 ppm of imidacloprid or a dose response probit 
analysis confirmed their susceptibility to imida-
cloprid. From 2009 to 2012, the Australian node 
performed valid assays on 97 field isolates from a 
total of 136 submissions, with no adult emergence 
observed at the 3-ppm imidacloprid discriminating 
dose. In addition to reviewing the data generated 
by this twelve-year initiative, this paper discusses 
lessons learned from the coordination and evolu-
tion of a complex project across geographically dis-
persed laboratories on three continents.
Introduction
The cat flea, Ctenocephalides felis felis, is widely 
recognised as the most common ectoparasite infest-
ing dogs and cats worldwide (Bond et al. 2007; Rust 
2005; Slapeta et al. 2011). Aside from being a prom-
inent cause of dermatitis and anaemia in these 
companion animals (reviewed by Dryden 2009), 
the cat flea is also a recognised vector for several 
disease agents, including Bartonella and Rickettsia 
spp. (Bitam et al. 2010), feline calicivirus (Mencke 
et al. 2009) and feline leukaemia virus (Vobis et al. 
2003, 2005). The subcutaneous filarial nematode 
Dipetalonema reconditum and the flea tapeworm 
Dipylidium caninum are also dependent upon the 
cat flea as an intermediate host (reviewed by Mehl-
horn 2012). The fact that C. felis vectors at least 
three zoonotic pathogens, Bartonella henselae, 
Rickettsia felis (Bitam et al. 2010) and Yersinia 
pestis (Mehlhorn 2012), shines a spotlight on this 
parasite in the public health arena (Richter et al. 
2002; Oteo et al. 2006; Mosbacher et al. 2010; 
Williams et al. 2011). Given the close association 
between owners and their pets, it can be argued 
that flea control is important not only from a veteri-
nary standpoint, but also as a protective measure 
for humans.
Approaches to cat flea control have evolved con-
siderably over time. Arguably the most significant 
change in the last twenty years has been a shift 
away from strategies that were underpinned by 
separate and often very frequent chemical treat-
ment of host and environment, towards reliance 
upon monthly application of treatment to host 
only (Rust 2005). This has been achieved thanks 
to the advent of several highly effective insecticide 
classes that maintain a high degree of residual 
adulticidal efficacy on the host and, in many cases, 
possess activity against off-host life stages in the 
host’s environment (Dryden 2009). These newer 
actives, namely imidacloprid, fipronil, selamectin, 
dinotefuran and spinosad, have facilitated owner 
compliance by providing convenience. It must be 
acknowledged, however, that the desirable persis-
tence of contemporary actives on the host is also a 
factor that renders potential vulnerability to the 
development of resistance. While no definitive evi-
dence of high-level C. felis field resistance to the 
neonicotinoid, avermectin, spinosyn or phenylpyra-
zole classes has been published to date, Payne and 
colleagues (2001) have previously highlighted a flea 
isolate that showed reduced susceptibility to topi-
cal fipronil from 20 days post treatment. Dryden 
and colleagues (2005) observed a decline in topical 
imidacloprid efficacy on cats challenged with infes-
tation 30 days post treatment. A study by Franc 
and Yao (2007) reported similar findings. It is not 
entirely clear whether the effective shortening of 
residual activity described in these reports reflects 
an absolute reduction in efficacy, or a reduced 
speed of kill (Kramer and Mencke 2001). It is worth 
noting that imidacloprid has been demonstrated 
to have a rapid direct contact effect upon fleas, as 
opposed to actives such as fipronil and selamectin, 
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which primarily require ingestion by fleas for puli-
cidal activity (Mehlhorn et al. 1999, 2001). Such 
differences in mode of action exert a profound effect 
upon speed of kill (Everett et al. 2000; Mehlhorn 
et al. 2001) and cautious interpretation is therefore 
required when comparing different actives under 
in vivo conditions. What is also unclear is how often 
suspect flea isolates, rarely reported in the litera-
ture, actually occur in the field, and whether such 
isolates are truly representative of the systematic 
development of resistance, or merely a reflection 
of the biological variability that might be expected 
in different flea populations (Kramer and Mencke 
2001).
Given the extensive global use of modern monthly 
adulticides against C. felis, a handful of suspect 
isolate responses identified in the literature should 
not be cause for undue alarm. It is, however, worth 
noting the well-documented historical development 
of high-level field resistance to predecessor insec-
ticide classes utilised in flea control, including the 
synthetic pyrethroids, carbamates and organophos-
phates (Rust and Dryden 1997). Driven largely by 
the recognised need to make more judicious use 
of newer insecticides has been the adoption of an 
integrated flea control (IFC) approach, which was 
borne out of the integrated pest management (IPM) 
concept first pioneered in the agricultural sector 
(Kogan 1998). The IFC approach advocates client 
education around flea biology, and reinforcement of 
adulticidal therapy by concurrent administration 
of insect growth regulators (IGRs) and employment 
of mechanical control practices such as regular vac-
uuming of the environment and use of flea traps 
(Dryden and Broce 2002).
A central tenant of integrated pest management is 
‘monitoring’ (Abrol and Shankar 2012). While this 
component of IPM traditionally refers to monitor-
ing of pest levels in the environment as a means 
to inform strategic control practices, it stands to 
reason that this rationale should extend to surveil-
lance around the development of insecticide resist-
ance in pest populations. To this end, an intensive 
C. felis imidacloprid susceptibility monitoring 
initiative was established in 1999, comprising an 
international group of collaborating laboratories. 
The basis of the monitoring undertaken by this 
group is a validated imidacloprid larval develop-
ment inhibition assay (Rust et al. 2002), for which a 
diagnostic dose (DD) has been determined to facili-
tate applicability to high-throughput field isolate 
screening (Rust et al. 2005). While the concept 
of utilising laboratory bioassays for monitoring 
parasiticide responses is not novel, the geographic 
scope, high degree of co-ordination and longevity 
of this monitoring initiative make it unique, par-
ticularly within the field of veterinary parasitology. 
With the programme entering its twelfth year of 
formal operations, it is timely to review the data 
generated by this work and to reflect upon lessons 
learned from the coordination and evolution of a 
complex project across geographically dispersed 
laboratories on three continents.
Materials and methods
Field isolate sampling
Field isolates of flea eggs collected from veterinary 
clinics were submitted to participating parasitol-
ogy laboratories in the United States (Auburn, Riv-
erside, Kansas), Germany (Monheim), the United 
Kingdom (London) and Australia (Brisbane). Upon 
enrolment into the programme, participating clin-
ics were supplied with a collection kit, comprising 
equipment and receptacles for flea egg collection, 
a detailed protocol and a questionnaire requesting 
information from the owner regarding their pet’s 
signalment, flea preventative treatment history 
and pertinent details of the animal’s environment, 
including the presence of other pets in the house-
hold (Blagburn et al. 2006; Rust et al. 2005).
Flea eggs were collected from patients identified 
to be carrying a flea burden according to the sup-
plied protocol (Rust et al. 2005). Briefly, the animal 
was placed into an environment conducive to col-
lection of flea eggs, typically a cage with mesh or 
grated floor, and provided with ad libitum water 
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and access to food and litter trays as required. An 
appropriate collection medium, such as newspaper, 
was placed underneath the cage. Following a peri-
od of between 4 h and 24 h, the animal was gently 
but thoroughly combed in order to remove flea eggs 
from the pelage. Eggs and debris collected under-
neath the cage were then transferred to a glass 
collection tube by use of a supplied sieve and fun-
nel. Where overnight shipping was required, tubes 
were packed into an appropriately insulated con-
tainer; for shorter same-day shipping and where 
climatic conditions were not extreme, tubes were 
bubble-wrapped for protection and shipped in an 
envelope.
Diagnostic dose bioassays
Upon receipt of a field submission, the responsi-
ble laboratory assessed the submitted material for 
flea egg quantity using a dissecting microscope. 
Where flea egg quantity was sufficient to permit 
conduct of a diagnostic dose (DD) bioassay, this 
was performed in accordance with the protocol 
outlined by Rust and colleagues (2005). Batches of 
20 eggs were placed into glass Petri dishes con-
taining either larval rearing media pre-treated to 
achieve a concentration of 3 ppm imidacloprid, or 
untreated media as a control. Up to six treated and 
three untreated replicates were prepared for each 
isolate where egg quantity permitted. As a further 
quality control measure, 20 eggs representative of 
in-house C. felis reference strains available at each 
site were placed on untreated media and incubated 
in parallel with the test isolate, in order to monitor 
conditions affecting hatchability. All dishes were 
incubated at 26 ± 2 °C and 80–85 % relative humid-
ity. Dishes were inspected after 12 d incubation in 
order to quantify larvae and pupae, and again at 
28 d to quantify emerged adults.
Debris testing
Where no egg hatch was observed in untreated 
replicates, and sufficient debris was present in the 
submitted material, a debris test was performed 
to screen for the presence of inhibitory residues. 
As outlined by Rust and colleagues (2011), this 
procedure entailed incubation of 20 control strain 
eggs with the debris (26 ± 2 °C and 80–85 % rela-
tive humidity). Failure of any control eggs to hatch 
and develop to adults after 28 d incubation was 
considered to indicate the presence of an inhibitory 
residue in the submission.
Repeat diagnostic dose bioassays
If 5 % or greater adult emergence was observed at 
the 3 ppm DD imidacloprid concentration, emerged 
adult fleas in the untreated control dishes were 
retained and placed on a cat in order to propagate 
the isolate. Where any participating laboratories 
did not have access to cats for propagation, pupae 
were promptly shipped to the nearest laboratory 
with this capacity. Following propagation, flea eggs 
were collected from the cat as previously described 
and a repeat 3 ppm imidacloprid DD bioassay was 
undertaken on three replicates of 20 eggs. At least 
one untreated control replicate was also setup in 
parallel. Emerged adult fleas were quantified in 
all dishes after 28 d incubation.
Full-dose bioassays and probit analysis
Field submissions with 5 % or greater adult emer-
gence in both preliminary and repeat DD bioas-
say testing were designated as isolates of interest. 
These isolates were further propagated on cats, and 
eggs were collected for use in full-dose response 
bioassays, conduct of which has been previously 
described (Rust et al. 2011). Briefly, larval rear-
ing medium was treated to achieve a gradient of 
nine imidacloprid concentrations (0.005, 0.01, 0.05, 
0.1, 0.3, 0.5, 1, 1.5 and 3 ppm). Twenty flea eggs 
were added to each dish, however a slight modifica-
tion for the full-dose bioassays was that eggs were 
not directly added to the media, but were instead 
carefully glued (UHU adhesive, Saunders Co., ME, 
USA) to the lid of each dish. This strategy sought 
to minimise impacts of cannibalism on egg hatch 
and larval development, given the higher degree 
of granularity sought from this level of testing. As 
for the DD bioassay, untreated media was used to 
S51
EctoparasitEs
monitor control mortality. Dishes were incubated 
at 26 ± 2 °C and 80–85 % relative humidity, with 
larvae and pupae counting at 12 d and quantifica-
tion of emerged adults at 28 d. Dose response pro-
bit lines were generated using the POLO software 
package (Version 1.0, LeOra Software, Menlo Park, 
CA, USA), permitting calculation of dose response 
slope, LC50 and LC95 values.
Results
Field isolate sampling
While the programme was formally initiated in 
2001, and 240 field isolates were submitted in 
this first year of operation, bioassay data was for-
mally recorded and archived from 2002 onwards. 
Between January 2002 and December 2012, a 
total of 2,307 field isolates were received across 
all sites. This was represented by 1,516 isolates 
obtained from cats (approx. 66 %) and 770 isolates 
from dogs (approx. 33 %); a host species was not 
recorded for 21 submissions. An overview of sub-
missions received across investigator sites is pro-
vided in Table 1. Submissions in North America 
totalled 1,331, 840 were received across Europe 
and 136 were received in Australia. Egg numbers 
in each submission ranged from zero to greater 
than 5,000, although only 2 % of submissions con-
tained more than 1,000 eggs. There was an average 
of 208 eggs per submission across the programme. 
In the Northern Hemisphere, which represents all 
sites outside of Australia, field isolate submission 
rate tended to peak between June and December, 
while submissions in the Southern Hemisphere 
(Australia) were highest between August and 
October.
Diagnostic dose bioassays
Of the 2,307 field isolates received between 2002 and 
2012, 1,685 (73 %) were suitable for placement into 
the imidacloprid DD bioassay. The greatest factor 
rendering isolates unusable was insufficient flea 
egg numbers. Of the 1,685 bioassays performed, 
1,367 (81 %) were valid as determined by hatching 
of at least one egg in control (untreated) media. 
The dorsal hind tibia of all emerging adults was 
examined and all specimens were consistent with 
C. felis and not the closely related species Cteno-
cephalides canis.
Discriminating dose bioassays conducted between 
2002 and 2012 exposed 95,729 individual C. felis 
eggs to the 3 ppm imidacloprid diagnostic dose. 
A total of 453 eggs (0.47 %), across 78 isolates, 
developed to adulthood. With respect to individual 
field submissions, flea emergence 5 % or greater 
at 3 ppm imidacloprid was observed in 38 of the 
1,367 tested in valid DD bioassays (2.8 %) (Table 1). 
No clear trends emerged with respect to either 
percentage egg emergence, which ranged yearly 
Table 1  Field submission, DD bioassay and survivorship data across participating sites
Laboratory
Total submissions 
(2002 – 2012)
Valid DD 
 bioassays
≥ 5 % survivorship 3 ppm 
imidacloprid
Repeat survivorship 3 ppm 
imidacloprid
Auburn 581 349 12 0
Kansas* 132 71 4 0
Monheim^ 491 313 12 0
Riverside 618 300 10 0
London* 349 237 0 0
Brisbane§ 136 97 0 0
Total 2307 1367 38 0
* Participated 2002 – 2006;  § Participated 2009 onwards; 
^ Samples from country of laboratory except Monheim with samples from across Europe including Germany, France & UK
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from < 0.1–1.6 %, or percentage field isolate survi-
vorship at 5 % or above, which ranged yearly from 
0.6–9.8 %. Of the 38 field isolates with 5 % or greater 
emergence at 3 ppm imidacloprid, 26 were sourced 
in North America and 12 from Europe. No emer-
gence at 5 % or greater was observed in any field 
isolates tested in the Southern Hemisphere (Aus-
tralia). With respect to invalid DD bioassays, 67 % 
of those for which debris could be tested showed nil 
control strain egg hatch suggesting the presence of 
an inhibitory residue.
Repeat diagnostic dose bioassays  
and full-dose bioassays
Propagation of isolates reaching or exceeding the 
5 % survivorship threshold in preliminary test-
ing could not be achieved in many cases. Factors 
impeding propagation included submissions con-
taining only enough eggs to run a single control 
replicate, resulting in few emerged adults, isolates 
for which control replicate hatchability was poor, 
isolates for which adults emerged from control 
media with poor fitness, and isolates that would 
not establish a fertile infestation even when appar-
ently fit adult fleas were placed onto the pelage of a 
cat. In all cases where adequate propagation could 
be achieved, repeat diagnostic dose testing failed to 
identify any isolates that reached or exceeded the 
5 % survivorship threshold a second time, implying 
that survival was a chance effect rather than indi-
cating a systematic shift in susceptibility.
While no isolates were deemed to require full-
dose gradient profiling on the basis of reaching or 
exceeding the survivorship threshold in two consec-
utive DD bioassays, some isolates were selected to 
undergo full-dose testing on the basis of moderate 
to high emergence of adult fleas (generally above 
10 %) in preliminary DD testing. Full-dose gradient 
profiling of these isolates is outlined in Table 2. 
None of these isolates had observed slope, LC50 or 
LC95 characteristics that were appreciably differ-
ent from the susceptible reference strains UCR, 
AUB and KS1.
Discussion
The imidacloprid susceptibility monitoring ini-
tiative reviewed in this paper represents the most 
ambitious and comprehensive surveillance project 
for any parasiticide in the veterinary sector. Over a 
period of twelve years, more than 1,300 individual 
cat flea isolates were screened with valid imida-
cloprid discriminating dose bioassays across three 
different continents. It is notable that just 0.47 % 
of all eggs assayed over this period developed to 
adult fleas in the presence of 3 ppm imidacloprid, 
and just 2.8 % of field isolates exceeded the diagnos-
tic dose threshold. Crucially, none of these isolates 
reached or exceeded the 5 % survival threshold on 
repeat testing, hence they could not be character-
ised as possessing field resistance to imidacloprid. 
As commented an earlier review of this initiative 
(Rust et al. 2011), it is likely that initial survivor-
ship in the DD bioassay that cannot be replicated 
represents a chance finding, and not the systematic 
development of resistance in that population.
It is worth reflecting upon data pertaining to the 
flea isolate submission process itself, since this 
can provide insight into seasonal prevalence of 
C. felis. In the Northern Hemisphere, sampling 
was undertaken year-round, with submission rate 
largely driven by the availability of fertile flea bur-
dens yielding eggs. Unsurprisingly, viable submis-
sions peaked during the warmer months between 
June and October, which is likely to represent the 
most active period for expansion of flea biomass 
within a household. However, as noted previously 
(Rust et al. 2011), the programme has consistently 
received Northern Hemisphere submissions during 
winter months, albeit at a reduced rate. This find-
ing advocates year-round treatment, particularly 
since winter flea burdens are likely to provide a 
strong impetus for a rise in flea numbers as warm-
er spring temperatures become more conducive to 
larval development. In Australia, submission rate 
was highly influenced by programme factors, since 
many isolates were sourced from patients admitted 
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to a desexing clinic associated with that laborato-
ry’s institution. This clinic was most active between 
August and October each year, hence submission 
rate was strongest during this period. The fact that 
isolate sampling at the Australian node of the pro-
gramme was largely sustained by submissions dur-
ing late winter and early spring is testament to the 
need for year-round use of flea preventatives in this 
country also, where much of the population resides 
in subtropical or mildly temperate climatic zones.
The incorporation of an Australian node in 2009 was 
an important means of expanding the geographic 
scope of the initiative. There were, however, sig-
nificant challenges to be overcome in establishing a 
participating laboratory on this isolated island con-
tinent. Aside from the marked geographic separa-
tion of the Australian laboratory from those in the 
USA and Europe, increasing internationalisation 
of the initiative required significant co-ordination 
to achieve import and export of biological materi-
als across international borders. Harmonisation of 
bioassay procedures has been an ongoing priority 
for the susceptibility monitoring team, a process 
that necessitates exchange of flea strains between 
laboratories. A primary goal upon establishment 
of the Australian node was shipment of a repre-
sentative C. felis field isolate from that country for 
full-dose response profiling in collaborating inter-
national laboratories. The dose response charac-
teristics of this isolate (AUS 1) were outlined in an 
earlier review of the initiative (Rust et al. 2011); 
it was determined to be phenotypically similar 
to the imidacloprid-susceptible reference strains 
UCR, KS1 and AUB. Profiling of this isolate was 
one step in a detailed series of laboratory visits, 
personnel training workshops and teleconferences 
that began as early as 2007. This comprehensive 
planning facilitated a relatively seamless entry of 
the Australian laboratory into the programme in 
2009.
Although only 97 Australian cat flea isolates have 
undergone valid DD bioassay testing to date, a 
reflection of the Australian laboratory’s nascent 
participation and the considerably smaller popu-
lation base in Australia as compared to North 
America and Europe, it is noteworthy that none of 
these isolates enabled 5 % or greater survivorship 
at 3 ppm imidacloprid. This uniform field suscep-
tibility is consistent with the dose response profile 
of AUS 1, which showed remarkable similarity to 
Table 2 Lethal doses of imidacloprid in larval rearing medium required to kill larval Ctenocephalides felis
Strain/isolate n slope ± SE LD50 (95 % CI)  D95 (95 % CI)
UCRI*§ 505 6.5 ± 1.16 1.25 (1.038 – 1.427) 2.24 (1.838 – 3.756)
UCRII*¤ 534 2.68 ± 0.292 0.12 (0.039 – 0.214) 0.48 (0.260 – 2.957)
AUBI*§ 394 5.5 ± 1.06 0.48 (0.395 – 0.564) 0.97 (0.802 – 1.383)
AUBII*¤ 410 4.64 ± 0.962 0.12 (0.094 – 0.158) 0.28 (0.212 – 0.518)
KS1*§ 1208 4.3 ± 0.62 0.73 (0.566 – 0.851) 1.75 (1.405 – 2.638)
MON* 403 3.44 ± 0.986 0.11 (0.070 – 0.154) 0.34 (0.239 – 0.673)
AUSI*§ 268 3.8 ± 0.80 0.48 (0.322 – 0.611) 1.29 (0.577 – 2.240)
AUSII* 458 3.16 ± 0.528 0.09 (0.059 – 0.120) 0.30 (0.207 – 0.608)
USA1§ 245 2.91 ± 0.492 0.18 (0.071 – 0.291) 0.67 (0.415 – 1.981)
USA2 435 4.56 ± 0.715 0.18 (0.141 – 0.216) 0.42 (0.341 – 0.560)
USA3 373 3.50 ± 0.689 0.21 (0.133 – 0.272) 0.62 (0.473 – 0.968)
USA4 438 2.81 ± 0.375 0.15 (0.100 – 0.198) 0.58 (0.419 – 0.964)
* Denotes susceptible reference strain; § Denotes that this data is as previously presented by Rust et al. 2011;  
USA# – field isolates sourced from United States; ¤ UCRII, AUBII and AUSII are the same continuously maintained strains as 
UCRI, AUBI and AUSI, UCRII, AUBII and AUSII data reflects profiling of these strains from 2009 onwards
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imidacloprid-susceptible reference strains main-
tained in the USA. It should be noted that, although 
this isolate was grouped with field survivors in a 
previous review of this work (Rust et al. 2011), 
this isolate was profiled as an exercise in bioassay 
harmonisation and not due to survivorship in the 
3 ppm imidacloprid DD bioassay.
Australia is a continent of unique isolation and bio-
diversity, where a rich agricultural heritage has 
seen widespread use of pesticides, notably persis-
tent organic compounds such as dieldrin and DDT 
(Kausik 1991). Although use of these compounds 
has now been banned in that country (Shivara-
maiah et al. 2002), background exposure of para-
site populations to bioaccumulative compounds 
creates uncertainty around how such populations 
might respond over time to novel parasiticides, par-
ticularly where non-specific metabolic resistance 
mechanisms are possible. Superimposed on this 
is the high degree of treatment compliance seen 
in Australian pet owners (Schantz 1991). While 
commendable, strong treatment compliance obvi-
ously drives selection for resistance. It is therefore 
heartening that, in the sixteen years since Hopkins 
and colleagues (1996) demonstrated high in-vivo 
efficacy of imidacloprid against a representative 
Australian C. felis isolate, there appears to have 
been no appreciable shift in imidacloprid suscepti-
bility in that country.
In an earlier review, Rust and colleagues (2011) 
commented on a significant reduction in control 
hatchability of field isolates over the first seven 
years of the programme, a trend that has contin-
ued through 2012. As outlined previously, it is 
possible that this reduction is due to receipt of an 
increased number of samples contaminated by an 
IGR, reflecting increased market-share of combina-
tion adulticide-IGR flea control products. Driven 
by concerns around IGR contamination of field iso-
lates, routine testing of debris from invalid DD bio-
assays has now been formally incorporated into the 
programme. In 2012, this testing revealed nil con-
trol strain egg hatch in debris from 67 % of invalid 
bioassays tested, suggesting IGR contamination in 
these submissions. While scrutinising debris with a 
control strain hatchability test is a useful prelimi-
nary screen for presence of inhibitory residues, it 
remains a somewhat blunt tool and requires that 
appreciable debris are present in submitted mate-
rial. Given that invalid bioassays are a waste of 
physical and human resources, it would be useful to 
be able to identify a contaminated submission upon 
receipt, and to be able to determine the identity of 
any inhibitory residue present. This is increasingly 
possible as technology advances, but requires fur-
ther investigation.
A further challenge that has emerged more recently 
is the difficulty encountered in propagating isolates 
that exceed the survivorship threshold in prelimi-
nary imidacloprid DD screening. It is not clear 
whether this is related to any kind of fitness cost 
associated with reduced susceptibility to imidaclo-
prid, because survivorship in preliminary 3 ppm 
DD bioassays is not definitive proof of imidacloprid 
tolerance. As previously discussed, all surviving 
isolates for which propagation was achieved did not 
survive subsequent 3 ppm imidacloprid exposure, 
and isolates for which full-dose response profiling 
was undertaken were comparable to susceptible 
reference strains. Fitness cost has been associated 
with imidacloprid resistance in crop pests (Baker 
et al. 2007; Liu and Han 2006), however, it is too 
early to determine whether this might also occur 
in C. felis, particularly since no imidacloprid-toler-
ant strains have yet been identified. While failed 
propagation of interesting isolates is a frustration 
in one sense, there is also opportunity for investiga-
tion into why many of these isolates do not readily 
favour propagation.
The longevity of this imidacloprid susceptibil-
ity monitoring initiative is testament to the high 
degree of cooperation between collaborating labo-
ratories, and the sustained and valued contribu-
tions of the many veterinary clinics participating 
in the programme. Coordinated surveillance pro-
jects such as the one described in this paper are a 
crucial undertaking; it would be foolish to assume 
that modern flea adulticides are immune from 
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resistance and even more foolish to expect that 
the golden age of parasiticide discovery enjoyed 
over the last 25 years will continue indefinitely. 
It is noteworthy, however, that in spite of scrutiny 
across three continents over an extended period, 
there continues to be an ongoing lack of C. felis field 
isolates showing resistance to imidacloprid. The 
adoption of integrated flea control practices is an 
excellent step that favours responsible insecticide 
use, however, these ideals must be reinforced by 
comprehensive surveillance using sensitive tools 
that are likely to detect emerging resistance long 
before it manifests as treatment failure in the field.
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